KPTI News and Press, Karyopharm Therapeutics Inc. From 08/04/22

Karyopharm Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress PR Newswire – Achieved Second Quarter 2022 Total Revenue of $39.7 Million , Up 76% Versus Second Quarter 2021; XPOVIO® (selinexor) Net Product Revenu...

Karyopharm Therapeutics ( NASDAQ: KPTI ) is scheduled to announce Q2 earnings results on Thursday, August 4th, before market open. The consensus EPS Estimate is -$0.64 (+9.9% Y/Y) and the consensus Revenue Estimate is $35.96M (+59.1% Y/Y). Over the last 3 months, EPS e...

Karyopharm to Participate at the 2022 Wedbush Pacgrow Healthcare Conference PR Newswire NEWTON, Mass. , Aug. 2, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, ...

Karyopharm to Report Second Quarter 2022 Financial Results on August 4, 2022 PR Newswire -- Conference Call Scheduled for Thursday, August 4, 2022 , at 8:00 a.m. ET -- NEWTON, Mass. , July 28, 2022 /PRNewswire/ -- Karyopharm Therapeut...

Commercial-stage biotech Karyopharm Therapeutics ( NASDAQ: KPTI ) and Italian pharma company Menarini Group announced on Thursday that the European Commission granted marketing authorization for a multiple myeloma therapy containing the oral exportin 1 inhibitor Nexpovio. ...

Karyopharm and Menarini Group Receive Full Marketing Authorisation from the European Commission for NEXPOVIO® (selinexor) for the Treatment of Patients with Multiple Myeloma After at Least One Prior Therapy PR Newswire – Based on Results from Phase 3 BOSTON...

Karyopharm Therapeutics ( NASDAQ: KPTI ) said eltanexor was granted fast track designation by the U.S. Food and Drug Administration (FDA) as monotherapy to treat patients with relapsed or refractory intermediate, high-, or very high-risk myelodysplastic syndromes (MDS...

Karyopharm Granted Regulatory Designations for Eltanexor for the Treatment of Myelodysplastic Syndromes PR Newswire – FDA Fast Track Designation and European Commission Orphan Medicinal Product Designation Underscore the Significant Need for New Treatm...

Cancer therapies developer Karyopharm Therapeutics (NASDAQ:KPTI) on Wednesday said it had been notified by Biogen (BIIB) that it had elected to terminate a 2018 asset purchase agreement between the two companies. As per the agreement dated Jan. 24, 2018, KPTI had sold to BIIB rights to its KP...

Karyopharm Therapeutics (NASDAQ:KPTI) has disclosed a ~$3.4M share sale by director Deepika Pakianathan. Pakianathan sold 538,784 shares of the company's common stock at $6.00 - $6.64 price range. Karyopharm (KPTI) recently appeared on Truist's list of companies with less than 12 months of ca...